Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.490
+0.020 (1.36%)
At close: Aug 13, 2025, 4:00 PM
1.470
-0.010 (-0.68%)
Pre-market: Aug 14, 2025, 8:59 AM EDT
Compugen Revenue
Compugen had revenue of $1.26M in the quarter ending June 30, 2025, a decrease of -81.24%. This brings the company's revenue in the last twelve months to $22.14M, down -48.16% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$22.14M
Revenue Growth
-48.16%
P/S Ratio
6.10
Revenue / Employee
$299,243
Employees
74
Market Cap
139.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
Dec 31, 2020 | 2.00M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CGEN News
- 6 days ago - Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients - Seeking Alpha
- 7 days ago - Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Compugen Reports Second Quarter 2025 Results - PRNewsWire
- 17 days ago - Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 - PRNewsWire
- 22 days ago - Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 - PRNewsWire
- 24 days ago - Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer - PRNewsWire
- 2 months ago - Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences - PRNewsWire
- 3 months ago - Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha